tradingkey.logo

Evolus Inc

EOLS
View Detailed Chart

9.150USD

0.0000.00%
Close 08/01, 16:00ETQuotes delayed by 15 min
589.71MMarket Cap
LossP/E TTM

Evolus Inc

9.150

0.0000.00%
Intraday
1m
30m
1h
D
W
M
D

Today

+2.58%

5 Days

-3.99%

1 Month

-1.29%

6 Months

-29.51%

Year to Date

-17.12%

1 Year

-33.98%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 7 analysts
BUY
Current Rating
23.000
Target Price
151.37%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

173
Total
5
Median
8
Average
Company name
Ratings
Analysts
Evolus Inc
EOLS
7
Biogen Inc
BIIB
37
Alnylam Pharmaceuticals Inc
ALNY
34
Vertex Pharmaceuticals Inc
VRTX
34
Amgen Inc
AMGN
33
Gilead Sciences Inc
GILD
30
1
2
3
...
35

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

1m
15m
30m
1h
D
W
M
1m
15m
30m
D
Sell
Sell(9)
Neutral(2)
Buy(2)
Indicators
Sell(4)
Neutral(2)
Buy(1)
Indicators
Value
Direction
MACD(12,26,9)
-0.048
Sell
RSI(14)
44.632
Neutral
STOCH(KDJ)(9,3,3)
22.894
Neutral
ATR(14)
0.420
High Vlolatility
CCI(14)
-136.551
Sell
Williams %R
67.742
Sell
TRIX(12,20)
-0.095
Sell
StochRSI(14)
90.282
Buy
Moving Average
Sell(5)
Neutral(0)
Buy(1)
Indicators
Value
Direction
MA5
9.112
Buy
MA10
9.311
Sell
MA20
9.345
Sell
MA50
9.480
Sell
MA100
10.420
Sell
MA200
11.914
Sell

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology in regulatory development. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins, and injectable dermal fillers.
Ticker SymbolEOLS
CompanyEvolus Inc
CEOMr. David Moatazedi
Websitehttps://www.evolus.com/
KeyAI